Recombinant Human Alpha 2-Antiplasmin protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg3041

---

Validation Data Gallery

• 

  Purity of Recombinant Human Alpha 2-Antiplasmin was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human Alpha 2-Antiplasmin protein Met28-Lys491 (Accession# P08697-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 5345
• Accession: P08697-1
• PredictedSize: 77.8 kDa
• SDS-PAGE: 80-95 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

SERPINF2 (Serpin Family F Member 2), also known as alpha-2-antifibrinolysis (alpha-2 antiplasmin, AAP), is a member of the serine protease inhibitor (Serpin) superfamily. This protein is a major inhibitor of fibrinolytic enzymes, which degrade fibronectin and various other proteins. Thus, SERPINF2 has an important role in the regulation of the blood coagulation pathway. Mutations in SERPINF2 can lead to alpha-2-fibrinolytic inhibitor deficiency, which is characterized by a severe bleeding tendency and is associated with the development of a variety of diseases including cardiovascular disease, thrombosis, and certain inflammatory disorders.

References:

1.Onishi S, et al. iScience. 2023;26(8):107271.                                                             
2. Kyung N. Lee, et al. Blood 2004; 103 (10): 3783–3788.                                       
3. Shao X, et al. J Hypertens. 2019;37(1):197-205.                                                    
4. Viganò S, et al. Thromb Res. 2018;166:60-62.